Vertex’s Kalydeco Gains FDA Panel Nod For Expanded Cystic Fibrosis Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-allergy committee endorsement for patients ages six years and older with the R117H mutation was driven by adult subgroup efficacy findings and doubts about the feasibility of conducting a new study in the rare disease pediatric population.